細胞凋亡，血管新生，抗體:藥物開發策略分析 是由出版商BioSeeker Group AB在2012年01月所出版的。
這份英文市場調查報告書包含5265 Pages 價格從美金5175起跳。
本報告以細胞凋亡及血管新生的機制、目標、影響領域及抗體的化合物領域為焦點，彙整各種的劑目標策略，化合物策略競爭基準，開發平台開發平台及最佳投資組合計劃等資料，為您概述為以下內容。
第1章 細胞凋亡
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:細胞凋亡治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 使用中的化合物策略:細胞凋亡藥物的各類型化合物的競爭基準
- 細胞凋亡的癌適應症症狀選擇
- 最佳投資組合計劃:細胞凋亡開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第2章 血管新生
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:影響血管新生的癌症治療藥目標策略
- 使用中的化合物策略:影響血管新生各化合物策略的治療樂物競爭基準
- 影響藥品作用的血管新生的癌症症狀
- 開發平台和最佳投資組合計劃:影響癌症治療藥開發平台血管新生的競爭基準
- 免責聲明
- 藥品目錄
- 企業目錄
第3章 抗體
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:癌症的抗體治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 抗體治療藥物的癌適應症症狀的選擇
- 最佳投資組合計劃:癌症的抗體治療開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
Abstract
Product Description
This triple analysis focuses on cancer drug development strategies by the two
mechanism/target/effect areas of Apoptosis and Angiogenesis and by the
compound strategy of Antibodies. Each of these three individual parts is
evaluated according to standardized criteria in a five pillar pipeline drug
assessment methodology to compare drug development strategies in oncology.
This makes it easy to find and compare analysis not only within one single
cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Apoptosis
The apoptosis report part comprises defined and up to date development
strategies for 171 apoptotic drugs in oncology (519 projects) within the
portfolio of 125 investigators, from Ceased to Pre-registration. This report
part extensively analyses 146 identified targets of apoptotic drugs, organized
into 120 drug target strategies, and assesses them in 53 different cancer
indications.
Part II: Angiogenesis
The angiogenesis report part comprises defined and up to date development
strategies for 239 drugs affecting angiogenesis in oncology within the
portfolio of 148 investigators, from Preclinical to Marketed. This report part
extensively analyses 174 identified targets of angiogenesis affecting drugs,
organized into 167 drug target strategies, and assesses them in 64 different
cancer indications.
Part III: Antibodies
The cancer antibody drug report part comprises defined and up to date
development strategies for 531 antibody drugs in oncology within the portfolio
of 196 companies world-wide, from Ceased to Marketed. The report extensively
analyses their 255 identified drug targets, organized into 266 drug target
strategies, and assesses them in 75 cancer indications.
The report is written for you to understand and assess the impact of
competitor entry and corresponding changes to development strategies for your
own portfolio products. It helps teams to maximize molecule value by selecting
optimal development plans and manage risk and uncertainty. The report serves
as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:
- * Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting cancer indications
that are known to be appropriate for your drug' s properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area
strategies
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally
to PPP and to stakeholders across your own organization. The report will also
be an important part of creating and implementing a market development plan
for cancer drugs to insure that the optimal market conditions exist by the
time the products are commercialized.
Table of Contents
Key Topics Covered:
Part I: Apoptosis
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (146 Drug Targets)
- 7 The Rise of New Products: How Mature, Unique and Clinically Validated
are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic
Pipeline? (120 Drug Target Strategies and 171 Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs
in Oncology by Compound Type (7 Different Compound Strategies)
- 9 Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer
Indications)
- 10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer
Therapeutic Pipeline by Investigator (125 Investigators)
- 12 Drug Index
- 13 Company Index
- Figures: Includes 6 Figures
- Tables: Includes 248 Tables
- Total Number of Pages: 803
Part II: Angiogenesis
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (174 Drug Targets)
- 7 Emerging New Products to Established Ones: Drug Target Strategies of
Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167
Drug Target Strategies and 239 Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs
Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies)
- 9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in
Oncology (64 Cancer Indications)
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the
Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148
Investigators)
- 10 Disclaimer
- 11 Drug Index
- 12 Company Index
- Figures: Includes 7 Figures
- Tables: Includes 300 Tables
- Total Number of Pages: 1227
Part III: Antibodies
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target Among Antibody Drugs in Oncology for the
Highest Therapeutic Outcome and Return on Investment (255 Drug Targets)
- 7 Emerging New Products to Established Ones: Drug Target Strategies of
Antibody Drugs in Oncology by their Highest Stage of Development (266 Drug
Targets Strategies and 531 Antibody Drugs)
- 8 Selecting Cancer Indication for Antibody Drugs (75 Cancer Indications)
- 9 Pipeline and Portfolio Planning: Competitive Benchmarking of the
Antibody Drug Pipeline in Oncology by Investigator (196 Investigators and 531
Antibody Drugs)
- 10 Disclaimer
- 11 Drug Index
- 12 Company Index
- Figures: Includes 5 Figures
- Tables: Includes 347 Tables
- Total Number of Pages: 1,944
Featured Companies
This Report Includes the Following Companies:
- A&G Pharmaceutical
- Abbott
- Abiogen
- Ablynx
- Abraxis BioScience
- AC Immune
- Acceleron Pharma
- Access
- ACT Biotech
- Actinium Pharmaceuticals
- Active Biotech
- Adherex
- Advanced Cancer Therapeutics
- Advanced Life Sciences
- Advantagene
- Advaxis
- Advenchen
- AEgera
- AEterna Zentaris
- Affibody
- Affimed Therapeutics
- Affitech
- Agennix
- AGY Therapeutics
- Aida Pharmaceuticals
- Alder Biopharmaceuticals
- Alethia Biotherapeutics
- Alexion
- Alfacell
- Algeta
- Alnylam
- ALSP
- Altor BioScience
- Ambit Biosciences
- Ambrilia Biopharma
- Amgen
- Amorfix Life Sciences
- Amphora
- Anavex Life Sciences
- Angiogen
- Angiogenex
- Angstrom Pharmaceuticals
- Ansaris
- Antisoma
- Aphios
- ApopLogic Pharmaceuticals
- Apricus Biosciences
- Arana Therapeutics
- Arca biopharma
- arGEN-X
- Ariad
- Arno Therapeutics
- ArQule
- Array BioPharma
- Ascenta Therapeutics
- Astellas
- Astex Therapeutics
- AstraZeneca
- Attenuon
- Austrianova
- Avaxia
- AVEO
- Bayer
- Berkeley Lab
- BioAlliance Pharma
- BioAxone
- Biocompatibles
- Biocon
- Biogen Idec
- BioInvent
- Biolex
- BioLineRx
- Bionovo
- Biosceptre
- Biotecnol
- Biotest
- BioVex
- Boehringer Ingelheim
- Bolder BioTechnology
- Bristol-Myers Squibb
- BTG
- Cancer Innovations
- Cancer Research Technology
- CDG Therapeutics
- Celecure
- Celgene
- Cell Therapeutics
- CellCeutix
- Celldex Therapeutics
- Cellmid
- Celltrion
- Celtic Pharma
- Center of Molecular Immunology
- Cephalon
- CG Therapeutics
- ChemoCentryx
- Chemokine Therapeutics
- China Sky One Medical
- Choongwae
- Circadian Technologies
- Coronado Biosciences
- Critical Outcome Technologies
- CSL
- Cue Biotech
- CuraGen
- CureTech
- Curis
- Cyclacel
- Cylene Pharmaceuticals
- CytImmune Sciences
- Cytochroma
- Daewoong
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Deciphera Pharmaceuticals
- Dendreon
- DiaMedica
- Dompe
- Dr Reddy' s
- Dyax
- Eisai
- Elan
- Eleos
- Eli Lilly
- Emergent BioSolutions
- Endocyte
- EntreMed
- Enzon
- EpiCept
- Epitomics
- EUSA Pharma
- Exelixis
- ExonHit Therapeutics
- Facet Biotech
- Faron Pharmaceuticals
- Favrille
- Femta Pharmaceuticals
- FibroGen
- Five Prime Therapeutics
- Fusion Antibodies
- Galaxy Biotech
- GammaCan
- Ganymed Pharmaceuticals
- Gene Techno Science
- Genencor
- Genentech
- Genmab
- Genomic Systems
- GenPat77
- Genta
- Genzyme
- Geron
- Gilead Sciences
- GlaxoSmithKline
- Gliknik
- GlycoGenesys
- Glycotope
- Green Cross
- Hawthorn Pharmaceuticals
- Hoffmann-La Roche
- Human Genome Sciences
- Hy BioPharma
- Idera Pharmaceuticals
- IDM Pharma
- ImClone Systems
- IMED
- Immune Pharmaceuticals
- ImmunoCellular Therapeutics
- ImmunoGen
- Immunomedics
- ImmuPharma
- Immutep
- Infinity Pharmaceuticals
- Innate Pharma
- InNexus Biotechnology
- Insmed
- Intracel
- Intradigm
- Introgen Therapeutics
- ISA Pharmaceuticals
- Isis Pharmaceuticals
- ISU ABXIS
- Johnson & Johnson
- KAI Pharmaceuticals
- Kaketsuken
- KaloBios
- Kalypsys
- Karus Therapeutics
- Kirin Pharma
- Kissei
- Kringle Pharma
- Kyowa Hakko Kirin
- Kyto Biopharma
- Lee' s Pharmaceutical
- LFB Biotechnologies
- LG Life Sciences
- Lorus Therapeutics
- MacroGenics
- MAT Biopharma
- Medarex
- MediGene
- MedImmune
- Medisyn Technologies
- Menarini
- Merck & Co
- Merck KGaA
- Merrimack
- Mersana Therapeutics
- MethylGene
- Micromet
- Mitsubishi Tanabe Pharma
- MolMed
- Morvus Technology
- Mycenax
- NeoPharm
- Neovacs
- Neuren
- NewSouth Innovations
- NIH
- Nippon Shinyaku
- NKT Therapeutics
- Non-industrial source
- Northwest Biotherapeutics
- Novacea
- Novartis
- Novelix
- Novogen
- Oasmia
- OncoMed
- Onconova
- OncoTherapy Science
- Oncothyreon
- Onyvax
- OSI Pharmaceuticals
- Oxford BioMedica
- OXiGENE
- Paladin Labs
- Panacea
- PanaGin
- PanGenetics
- Patrys
- Pepscan Therapeutics
- PepTx
- Peregrine Pharmaceuticals
- Perseus Proteomics
- Pfizer
- Pharmacopeia
- Pharmacyclics
- PharmaMar
- Pharminox
- Philogen
- PhiloGene
- Pierre Fabre
- Prima Biomed
- ProCell Therapeutics
- Prochon Biotech
- Progen
- Progenics Pharmaceuticals
- Protein Sciences
- PTC Therapeutics
- Ramot
- Reata Pharmaceuticals
- Recepta biopharma
- Receptor BioLogix
- Regeneron
- Regulon
- Rexahn
- Rigel
- Sanofi-Aventis
- Santaris Pharma
- SBI Biotech
- Scancell
- SciClone Pharmaceuticals
- Seattle Genetics
- Semafore Pharmaceuticals
- Shenogen
- Sigma-Tau
- Simcere Pharmaceuticals
- Spear Therapeutics
- SRI International
- Stainwei Biotech
- Sunol Molecular
- SuperGen
- SuppreMol
- Switch Pharma
- Symbiotec
- Symphogen
- Synageva BioPharma
- SynDevRx
- SynerGene Therapeutics
- Takeda
- Targa Therapeutics
- Tau Therapeutics
- Taxolog
- TeGenero
- Telik
- Teva
- Thallion Pharmaceuticals
- Therapure Biopharma
- ThromboGenics
- Tigris Pharmaceuticals
- Titan Pharmaceuticals
- Tolerx
- ToolGen
- TopoTarget
- Tracon Pharmaceuticals
- Transgene
- Trillium Therapeutics
- Trion Pharma
- UCB
- United Therapeutics
- Vaccinex
- Wakunaga
- Vascular Biogenics
- VasGene Therapeutics
- VBL Therapeutics
- Vertex Pharmaceuticals
- Wilex
- VioQuest
- Viragen
- Viralytics
- ViroTarg
- Viventia Biotech
- Wyeth
- XBiotech
- Xencor
- Xerion
- Xoma
- Y' s Therapeutics
- YM BioSciences
- Zenotech
- ZymoGenetics
Featured Drugs
A Shortlist of Drugs Included are:
- 131I-tositumomab
- 2-methoxyestradiol
- abagovomab
- ABT-263
- AEG-35156
- aflibercept
- afutuzumab
- alemtuzumab
- alvocidib
- AMG-386
- apatinib
- Apomab
- ARQ-197
- AS-1411
- atiprimod dimaleate
- ATN-224
- axitinib
- belinostat
- bevacizumab
- BIBF-1120
- brentuximab vedotin
- brivanib alaninate
- BZL-101
- canfosfamide hydrochloride
- catumaxomab
- CBLC-102
- cediranib
- cenersen
- cetuximab
- cilengitide
- cintredekin besudotox
- combretastatin A-4 prodrug
- conatumumab
- CS-1008
- denosumab
- dulanermin
- endostatin
- enzastaurin hydrochloride
- everolimus
- farletuzumab
- fosbretabulin tromethamine
- galiximab
- GCS-100LE
- gemtuzumab ozogamicin
- girentuximab
- GRN-163L
- HBP-347
- HE-3235
- ibritumomab tiuxetan
- idronoxil
- indisulam
- INGN-241
- INGN-401
- inotuzumab ozogamicin
- ipilimumab
- ISIS-23722
- kahalalide F
- linifanib
- lonaprisan
- lumiliximab
- mapatumumab
- MGCD-0103
- midostaurin
- MKC-1
- motesanib diphosphate
- motexafin gadolinium
- naptumomab estafenatox
- necitumumab
- nimotuzumab
- obinutuzumab
- oblimersen sodium
- ofatumumab
- oregovomab
- OTS-102
- panitumumab
- panobinostat
- PARP inhibitors
- PAT-SC1
- patupilone
- pazopanib hydrochloride
- PCI-24781
- pertuzumab
- plitidepsin
- quarfloxacin
- ramucirumab
- Reditux
- retaspimycin
- Rh-Apo2L
- ridaforolimus
- rituximab
- sagopilone
- seliciclib
- sorafenib tosylate
- sunitinib malate
- talactoferrin alfa
- thymalfasin
- tigapotide triflutate
- tipifarnib
- TLN-232
- trastuzumab
- triciribine
- TRU-016
- vandetanib
- voreloxin
- VX-944
- XL-184
- XL-647
- zalutumumab
- zanolimumab
